Advertisement

Medical Oncology

, Volume 11, Issue 1, pp 1–6 | Cite as

Growth factors and hematopoietic recovery

  • Subhash C. Gulati
  • Ravi Gopal
  • Judith B. Prowda
  • Stanislov Spanik
  • Maneesh Jain
  • Ajay Gopal
Review Article
  • 26 Downloads

Abstract

Availability of hematopoietic growth factors (GC-SF, GM-CSF, erythropoietin,etc.) has started a new arena of dose-intensification. The use of such growth factors has resulted in faster hematopoietic recovery of cancer patients and now offers several new treatment modifications. These include: (1)dose-intensification without hematopoietic stem cell support, (2) speedier hematopoetic recovery after hematoablative therapy and stem cell transplantation (allogeneic or autologous); (3) use of combination of growth factors, and (4) improvement in the delivery of anti-microbial drugs which are toxic towards hematopoietic cells (Gancyclovir, Bactrim,etc.). The above treatment strategies are under active clinical trials and can provide improved, cost-effective methods of treating patients with cancer.

Key Words

Growth factors hematopoietic recovery 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lieschke G J and Burgess A W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.N Eng J Med,327,28–35 (1992).Google Scholar
  2. 2.
    Lieschke G J and Burgess A W. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.N Eng J Med,327,99–106 (1992).Google Scholar
  3. 3.
    DeWitte T, Gratwohl A, Van Der Lely N, Bacigalupo A, Stern A C, Speck B, Schattenberg A, Nissen C, Gluckrnan E and Fibbe W E. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic Tcelldepleted bone marrow transplantation.Blood,79,1359–1365 (1992).Google Scholar
  4. 4.
    Fritsch G, Emminger W, Buchinger P, Printz D and Gadner H. CD34+ cell proportions in peripheral blood correlate with colonyforming capacity.Exp Hematol,19,1079–1083 (1991).PubMedGoogle Scholar
  5. 5.
    Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Stern A C, Landsdorp P M, Bonadonna G and Ganni A M. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients.Blood,77,400–409 (1991).PubMedGoogle Scholar
  6. 6.
    Janssen W E, Farmelo M J, Lee C, Smilee R, Kronish L and Elfenbein G J. The CD34+ cell fraction in bone marrow and blood is not universally predictive of CFUGM.Exp Hematol 20,528–530 (1992).PubMedGoogle Scholar
  7. 7.
    Siena S, Bregni M, Gianni A M and Janssen W E. Estimation of peripheral blood CD34+ cells for autologous transplantation in cancer patients:Exp Hematol,21,203–205 (1993).PubMedGoogle Scholar
  8. 8.
    Jones R J, Sharkis S J, Celano P, Colvin O M, Rowley S C and Sensenbrenner L L. Progenitor cell assays predict hematopoietic reconstitution after syngeneic transplantation in mice.Blood,70,1186–1192 (1987).PubMedGoogle Scholar
  9. 9.
    Gulati S C.Purging in bone marrow transplantation. R.G. Landes, CRC Press, 2000 Corporate Boulevard, Boca Raton, FL 33431 (1993).Google Scholar
  10. 10.
    Douay L, Gorin N C, Mary J Y, Lemarie E, Lopez M, Najman A, Stachowiak J, Giarratana M C, Bailou C, Salmon C and Duhamel G. Recovery of CFUGM from cryo-preserved bone marrow andin vivo evaluation after autologous bone marrow transplantation are predictive of engraftment.Exp Hematol,14,358–365 (1986).PubMedGoogle Scholar
  11. 11.
    Atkinson K, Biggs J C, Downs K, Juttner C, Bradstock K, Lowenthal R M, Dale B, Szer J. GMCSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes and Iymphocytes.Aust NZ J Med 21,686–692 (1991).Google Scholar
  12. 12.
    Nemunaitis J, Rabinowe S N, Singer J W, Bierman P J, Vose J M, Freedman A S, Onetto N, Giltis S, Oette D, Gold M, Buckner D, Hansen J A, Ritz J, Appelbaum F R, Armitage J O, Nadler L M. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for Iymphoid cancer.N Eng J Med,324,1773–1778 (1991).Google Scholar
  13. 13.
    Gianni A M, Bregni M, Stern A C, Siena S, Tarella C, Pileri A and Bonadonna G. granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation.Lancet, 580–585 (1989).Google Scholar
  14. 14.
    Gulati S C and Bennett C L. granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin Disease.Annals of lnternal Medicine,116,177–182 (1992).Google Scholar
  15. 15.
    Bot F J, van Eijk L, Schipper P, Backx B and Lowenberg B. Synergistic effects between GMC-SF and GC-SF or MC-SF on highly enriched human marrow progenitor cells.Leukemia,4,325–328 (1990).PubMedGoogle Scholar
  16. 16.
    Morstyn G, Campbell L, Lieschke G, Layton J E, Maher D, O’Connor M, Green M, Sheridan W, Vincent M, Alton K, Souza L, McGrath K, Fox R M. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.J Clin Oncol,7,1554–1562 (1989).PubMedGoogle Scholar
  17. 17.
    Bender J G, Bik To L, Williams S, Schwartzberg L S. Defining a therapeutic dose of peripheral blood stem cells.J Hematotherapy,1,329–341 (1992).Google Scholar
  18. 18.
    To L B, Haylock D N, Dyson P G, Thorp D, Roberts M M, Juttner C A. An unusual patter of hematopoietic reconstitution in patients with acute myeloid leukemia transplanted with autologous recovery phase peripheral blood.Bone Marrow Transplant,5,109–114 (1990).Google Scholar
  19. 19.
    Harrison D E, Jordan C T, Zhong R K and Astle C M. Primitive hemopoietic stem cells: direct assay of most productive populations by competitive repopulation with simple binomial, correlation and covariance calculations.Exp Hematol,21,206–219 (1993).PubMedGoogle Scholar
  20. 20.
    Lopez M, Mary J Y, Sainteny F.Invitro purging of bone marrow with mafosfamide synergizes withinvivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.Exp Hematol,21,311–318 (1993).PubMedGoogle Scholar
  21. 21.
    Brenner M K, Rill D, Moen R C,et al. Genemarking to trace origin of relapse after autologous bone marrow transplantation.Lancet,341,85–86 (1993).PubMedCrossRefGoogle Scholar
  22. 22.
    MacKintosh F R, Adlish J, Hall S W, St.Joer S, Smith E, Tavassoli M and Zanjani E D. Suppression of normal human hematopoiesis by cytomegalovirusinvitro.Exp Hematol,21,243–250 (1993).PubMedGoogle Scholar
  23. 23.
    Schwartzberg L S, Birch R, Hazelton B, Tauer K W, Lee P Jr, Altemose R, George C, Blanco R, Wittlin F, Cohen J, Muscato J and West W H. Peripheral blood stem cell mobilization by chemotherapy with or without recombinant human granulocyte colony-stimulating factor.J Hematotherapy,1,317–327 (1992).Google Scholar
  24. 24.
    Moore M A S. Does stem cell exhaustion result from combining hematopoeitic growth factors with chemotherapy? If so, how do we prevent it?Blood,80,3–7 (1992).PubMedGoogle Scholar
  25. 25.
    Bitran J, White L, Okuno T, Martinec J, Samuels B and Klein L. Mobilization of early hematopoietic progenitors after high dose cyclophosphamide alone and cyclophosphamide and thiotepa.ASCO,12,1527 (1993).Google Scholar
  26. 26.
    Fleischlauer K, Kernan N, O’Reilly R J, Dupont B and Young Yang S. Bone marrowallograft rejection by Tlymphocytes recognizing a single amino acid difference in HLAB44.N Engl J Med,323,1381–1822 (1990).Google Scholar
  27. 27.
    Emerson S G, Sieff C A, Gross R G, Rozans M K, Miller R A, Rappeport J M and Nathan D G. Decreased hematopoietic accessory cell function following bone marrow transplantation.Exp Hematol,15,1013–1021 (1987).PubMedGoogle Scholar
  28. 28.
    Straus S E, Cohen J, Tosato G and Meier J. Epstein Barr virus infections: Biology, pathogenesis, and management.Annals of Internal Medicine,118,45–58 (1993).PubMedGoogle Scholar
  29. 29.
    Anderson L J and Torok T. Human Parvovirus B19.NEJM,321,536–538 (1989).PubMedGoogle Scholar
  30. 30.
    Matthews J H. Pulmonary toxicity of ABVD chemotherapy and GCSF in Hodgkin’s disease: Possible synergy.Lancet,342,988 (1993).PubMedCrossRefGoogle Scholar
  31. 31.
    Iki S, Yoshinaga K, Ohbayashi Y,et al. Cytotoxic drug-induced pneumonia and possible augmentation b GCSFClinical attention.Ann Hematol 66,217–218 1993.PubMedCrossRefGoogle Scholar
  32. 32.
    Brugger W, Bross K, Fisch J,et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, if osfamide, and cisplatin.Blood,79,1193–1200 (1992).PubMedGoogle Scholar
  33. 33.
    Neidhart J, Mangalik A, Stidley C, Tebich S, Sarmiento L, Pfile J, Oette D and Oldhan F. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy.J Clin Oncol,10,1460–1469 (1992).PubMedGoogle Scholar
  34. 34.
    Wing E J, Magee D M, Whiteside T L, Kaplan S S and Shadduck R K. Recombinant human granulocyte-macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor a and interferon in cancer patients.Blood,73,643–646 (1989).PubMedGoogle Scholar
  35. 35.
    Rabinowitz J, Petros W P, Stuart A R and Peters W P. Characterization of endogenous cytokine concentrations alter highdose chemotherapy with autologous bone marrow support.Blood,81,2452–2459 (1993).PubMedGoogle Scholar
  36. 36.
    Kawano Y, Takaue Y, Saito S I, Sato J, Shimuzu T, Suzue T, Hirao A, Okamoto Y, Abe T, Watanabe T, Kuroda Y, Kimura F, Motoyoshi K and Asano S. Granulocyte colony-stimulating factor macrophage CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts.Blood,81,856–860 (1993).PubMedGoogle Scholar
  37. 37.
    Locatelli F, Pedrazzoli P, Barosi G, Zecca M, Porta F, Liberato L, Gambarana D, Nespoli L and Cassola M. Recombinant human erythropoietin is effective in correcting erythropoietin-deficient anemia after allogeneic bone marrow transplantation.British J Haematol,80,545–549 (1992).CrossRefGoogle Scholar
  38. 38.
    Miller C B, Platanias L C, Mills S R, Zahurak M L, Ratain M J, Ettinger D S and Jones R J. Phase 111 trial of erythropoietin in the treatment of cisplatinassociated anemia.J Natl Cancer Inst,84,98–103 (1992).PubMedCrossRefGoogle Scholar
  39. 39.
    Platanias L C, Miller C B, Mick R, Hart R D, Ozer H, McEvilly J M, Jones R J and Ratain M J. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.J Clin Oncol,9,2021–2026 (1991).PubMedGoogle Scholar
  40. 40.
    Gulati S C, Bennett C, Phillips J and Van Poznak C. GMCSF as an adjunct to autologous bone marrow transplantation.Stem Cells,11,20–25 (1993).PubMedCrossRefGoogle Scholar
  41. 41.
    Crown J, Kritz A, Vahdat L, Reich L, Moore M, Hamilton N, Schneider J, Harrison M, Gilewski T, Hudis C, Gulati S C and Norton L. Rapid administration of multiple cycles of highdose myelosuppressive chemotherapy in patients with metastatic breast cancer.JCO,11,1144–1149 (1993).Google Scholar
  42. 42.
    Rubinstein P, Rosenfield R E, Adamson J W and Stevens C E. Stored placental blood for unrelated bone marrow reconstitution.Blood,81,1679–1690 (1993).PubMedGoogle Scholar
  43. 43.
    Brugger W, Klaus J B Glattet al. Mobilization of tumor cells and hematopoietic progenitor cell into peripheral blood of patients with solid tumors.Blood,83,636–640 (1994)PubMedGoogle Scholar
  44. 44.
    Gulati S C. Did we focus on the most important issues in the use of growth factors and stem cell transplantation?J Clin Oncol,12,650–652 (1994).PubMedGoogle Scholar
  45. 45.
    Kutsogiannis D J, Crowther M A and Lazarovitis A I, Granulocyte-macrophage colony-stimulating factor for the therapy of cytomegalovirus and gancyclovir-induced leukopenia in a renal transplant recipient.Transplantation,53,930–932 (1992).PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1994

Authors and Affiliations

  • Subhash C. Gulati
    • 1
  • Ravi Gopal
    • 1
  • Judith B. Prowda
    • 1
  • Stanislov Spanik
    • 1
  • Maneesh Jain
    • 1
  • Ajay Gopal
    • 1
  1. 1.Division of Hematology OncologyCornell University Medical CollegeNew York

Personalised recommendations